MET expression by immunohistochemistry as a biomarker in pancreatic neuroendocrine tumours
INTRODUCTION: MET (c-MET) is a receptor tyrosine kinase implicated in numerous cancers, including pancreatic neuroendocrine tumours (pNETs), by promoting cell proliferation, survival, invasion and angiogenesis. Recognizing its oncogenic potential, there is significant interest in MET-targeted therapies for malignancies like pNETs, which often develop treatment resistance. Immunohistochemistry (IHC) has become a practical method for detecting MET overexpression in cancers. This study evaluates MET expression in pNETs by IHC and assesses its correlation with prognostic variables and survival outcomes. METHODS AND RESULTS: Tissue microarrays containing well-differentiated neuroendocrine tumours from the gastrointestinal tract were analysed. The study included 125 pNET cores from 112 patients after application of inclusion criteria. MET expression was determined using the H-score system. Different variables were assessed for H-score distribution and cross-tables. Survival analyses were conducted based on progression-free survival and overall survival. Positive MET expression was found in 83.5% of cases. Higher MET H-scores were seen in patients with lymphovascular invasion (LVI), distant metastases and higher tumour grade (P < 0.05). When assessing different variables for higher MET H-scores, a significant association emerged at the 150-cut-off-point for LVI, perineural invasion, radiological evidence of progression and overall survival. For survival analysis, at a MET H-score threshold of 200, high MET expression was significantly associated with shorter progression-free survival (mean 8.7 versus 13.4 years, P < 0.05) and overall survival (mean 3.6 versus 7.7 years, P < 0.05). CONCLUSION: Elevated MET expression is linked to adverse histopathological features and worse clinical outcomes in pNET. Standardizing MET IHC evaluation is critical as anti-MET therapies develop, and identifying patients likely to benefit from these treatments remains essential.
Authors
- David S. Klimstra (ORCID: https://orcid.org/0000-0001-8814-1702)
- Leanne Brown (ORCID: https://orcid.org/0009-0002-3940-4064)
- Felipe Carrasco-Tenezaca (ORCID: https://orcid.org/0000-0002-4715-6542)
- Guannan Gong (ORCID: https://orcid.org/0000-0002-4972-6705)
- Samuel G. Katz (ORCID: https://orcid.org/0000-0003-1744-8568)
- John W. Kunstman (ORCID: https://orcid.org/0000-0002-2618-4173)
- Gabrielle Carmichael
- Pohan Chen (ORCID: https://orcid.org/0000-0002-3823-5337)
- Pamela L. Kunz (ORCID: https://orcid.org/0000-0003-1613-3919)
- Theresa Marciano
Institutions
- Yale Cancer Center (US)
Publication Details
- Journal
- Histopathology
- Published
- 2026-09-01
- DOI
- https://doi.org/10.1111/his.70273
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Yale University
- Yale Cancer Center
- National Cancer Institute